Anzeige
Mehr »
Montag, 21.07.2025 - Börsentäglich über 12.000 News
Alarm am Metallmarkt: Kupfer unter Strom: USA rüsten sich - was das für Anleger bedeutet
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PPQK | ISIN: US4495851085 | Ticker-Symbol: 1K0
Tradegate
21.07.25 | 16:21
1,100 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
IGM BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
IGM BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0101,06016:32
1,0901,10016:31

Aktuelle News zur IGM BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.07.IGM Biosciences climbs on merger deal with Concentra2
01.07.Concentra acquires IGM Biosciences, continuing M&A streak with struggling biotechs4
01.07.IGM Biosciences stock soars after Concentra acquisition deal3
01.07.IGM Biosciences, Inc. - 8-K, Current Report-
01.07.Concentra to acquire IGM Biosciences for $1.247 per share plus CVR2
IGM BIOSCIENCES Aktie jetzt für 0€ handeln
01.07.IGM Biosciences, Inc.: IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right185MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, today...
► Artikel lesen
11.06.IGM Biosciences, Inc. - 8-K, Current Report2
29.05.IGM Biosciences, Inc. - 8-K, Current Report2
13.05.IGM Biosciences, Inc. - 10-Q, Quarterly Report1
08.05.IGM Biosciences, Inc. - 8-K, Current Report3
08.04.IGM Biosciences slips as Bank of America downgrades on liquidity concerns4
07.03.Stifel maintains IGM Biosciences stock hold with $2.50 target5
06.03.IGM Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
06.03.IGM Biosciences, Inc. - 10-K, Annual Report1
09.01.IGM Biosciences, Inc.: IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs233- Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) - - Company reducing its workforce by 73% - - Cash and investments of $183.8 million (unaudited) as of December...
► Artikel lesen
08.11.24IGM Biosciences, Inc.: IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update226- Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 - - IGM-2644 (CD38 x CD3) expected to enter...
► Artikel lesen
01.10.24Pre-market Movers: Shattuck Labs, SITE Centers, IGM Biosciences, ATIF Holdings, Arqit Quantum952OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.45 A.M. ET).In the Green SITE Centers Corp. (SITC) is up over 53% at $18.12. ATIF...
► Artikel lesen
30.09.24IGM Biosciences, Inc.: IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity393- Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus - - Mary...
► Artikel lesen
14.08.24IGM Biosciences, Inc.: IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update237- Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 - - Second dose cohort cleared in imvotamab rheumatoid arthritis...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1